絞り込み

17057

広告

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.

著者 Gibney GT , Hamid O , Lutzky J , Olszanski AJ , Mitchell TC , Gajewski TF , Chmielowski B , Hanks BA , Zhao Y , Newton RC , Maleski J , Leopold L , Weber JS
J Immunother Cancer.2019 Mar 20 ; 7(1):80.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (7view , 0users)

Full Text Sources

Medical

Research Materials

Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, in advanced melanoma (NCT01604889).
PMID: 30894212 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード